drugset / Trial / NCT04204629

Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Subjects

NCT04204629

Phase 1 Completed 25 enrolled Hanmi Pharmaceutical Company Limited
RandomizedCrossoverOpen-labelTreatment

Summary

Primary objective - To evaluate food effect on the pharmacokinetics and the pharmacodynamics (PD) of a single oral dose of HIP1601 in healthy subjects under fed or fasting condition. Secondary objectives \- To evaluate the safety of single oral dose of HIP1601 in healthy subjects under fed or fasting condition.

Timeline

Start
2020-01-13
Primary completion
2020-02-20
Completion
2020-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 40 mg Oral

Indications

No indication recorded.